REGISTRATION FOR THE ROUND TABLES IS NOW CLOSED. THANK YOU FOR YOUR INTEREST.
You are invited to request participation in one of our round tables.
PLEASE NOTE: Participation is only for registered attendees of the 2nd Summit of the Israeli Society for HealthTech.
Round Table participation will be granted on first-come-first-served basis and our team will contact you directly if you are given a slot at the round table of your choice. **Please do not submit more than one request.**
Scroll down to submit your request in the form below!
The Round Tables will be held at 13:30-14:15 in an area adjacent to the main conference hall.
Please complete the form below to submit your request to participate.
Engage with like-minded professionals and experts from the healthcare and healthtech arena and explore key challenges and opportunities in leveraging innovation in medical practice. The unique round table discussions at the 2nd Summit of the Israeli Society for HealthTech will offer in-depth discussion and are designed to result in actionable insights.
TABLE 1
Financing Innovation in Healthcare: New Models Required
Innovation in healthcare requires strategic investments and collaborations. Israel exemplifies this by leveraging its strong startup ecosystem. Globally, prioritizing cost-effective technologies and public-private partnerships are driving progress. Government incentives and venture capital investments support innovative solutions, such as telemedicine and AI-driven diagnostics, which improve efficiency and reduce costs.
But is this enough?
Around this table we will discuss the possibilities in fostering a collaborative environment between academia, industry, and government, in order to further demonstrate targeted funding for innovation and enhance healthcare delivery, even amidst financial constraints.
Sponsored by:
Moderator:
Dr. Adv. Noam Asna MD, LLM, MHA, M.oncol.
Head of Inpatient Oncology, Helmsley Cancer Center, Shaare Zedek MC
TABLE 2
Critical Aspects of Founders’ Agreements and Company Formation
This discussion will cover essential topics including how to slice the pie and structure equity effectively; the assignment of roles and responsibilities; and the establishment of decision-making procedures.
We will delve into handling IP assignment, managing issues related to departing founders, and strategies for avoiding tax pitfalls.
Additionally, we will discuss preparing for investment and due diligence, ensuring that your company is ready to attract and secure funding.
This comprehensive discussion aims to equip founders with the knowledge to build a solid foundation for their startups.
Sponsored by:
Moderator:
Hili Rashkovan
Partner, Chair of the IL Technology Transactions Practice Group, Pearl Cohen
TABLE 3
Advancing Solutions for Optimizing Multidisciplinary Decisions in the Daily Management of Complex Patients
In recent years, we have witnessed an increase in patients suffering from severe and complicated diseases simultaneously, such as different types of cancer, complex chronic diseases, or autoimmune diseases, requiring the involvement of multiple disciplines.
The importance of holistic treatment is increasing: New regulations for information mobility, multidisciplinary decision-making meetings at crucial stages, and the establishment of data-sharing platforms.
However, there are still many complexities, especially in day-to-day care when unexpected changes occur throughout the patient’s journey, making it more challenging to make decisions in view of all those involved in the patient’s care.
At this round table we will discuss whether and how advanced technology and collaborations could maximize the existing data-sharing platforms to enable optimal management of decision making regarding the complex patient with a 360-degree view.
Sponsored by:
Moderators:
Liat Gottlieb
Managing Director Israel, Johnson & Johnson Innovative Medicine
Dr. Shirley Shapira MD
Senior Hematologist, Meir Medical Center
Senior Hematologist and Hematology Consultant, Maccabi HMO Headquarters
TABLE 4
Yes, There Is Still Much To Say and Debate About Gen AI. What? How? For What and When?
Generative AI is the hot(test) topic. But when you introduce Gen AI into the world of medicine, the issue becomes challenging and even controversial. We invite you to a round table on Gen AI generating a healthier world. IMA and Medika will lead a brainstorming session, trying to explore and certainly debate on what is Gen AI? What is its place in the clinical world? Where can you already see signs of Gen AI? For the conservatives among us – is this a gimmick/trend/niche or real disruption? What makes the physician/clinician always distinct from Gen AI? How will the regulation deal with a system that not only changes (which we are used to from “normal” ML systems) but also generates?
Sponsored by:
Moderators:
Moshe Klaiman
CEO & CTO, Matrix Medika
Arnon Zangvil
Healthcare Technology Expert
TABLE 5
Crafting a Venture That Captivates Investors
What really interests investors in early-stage projects in the health world? Let’s debunk the myths and understand in depth what a real investor is looking for. In this unique roundtable session, we will dive into an innovative project in the medical field and analyze it from the perspective of experienced investors.
Together, we will discover the critical parameters for success: potential market size, a sustainable business model, a groundbreaking technological solution, an in-depth analysis of the competition, and much more.
Don’t miss this unique opportunity to understand what really drives investment decisions and take a significant step towards the success of your project!
Moderators:
Gal Atarot
CTO, MEDX Xelerator
Inbar Grebler
Business Development Manager, MEDX Xelerator
TABLE 6
Regulatory Challenges in Early Development of Bio-convergence Technologies
Early-stage healthtech R&D teams rarely spend resources to accurately consider the regulatory landscape of their technology and face the risk of being required to adjust their clinical design.
In bio-convergence (BC) companies this risk is elevated due to inherent ambiguities regarding the regulatory pathway that relates to them.
The Medical Technologies, Innovation, Informatics & Research (MTIIR) team at the Israel Ministry of Health (IMOH) is addressing this challenge, attempting to resolve the ambiguity in a globally unique method, working closely with R&D teams for the duration required to better align their efforts with the high standard set by healthtech regulation.
Starting with given use cases that shall be presented in this round table, participants are welcome to discuss the future of BC-healthtech regulation and prepare for it.
Moderators:
Anat Boehm-Cagan PhD
Head of Medical Technologies Regulation and Regulatory Partnerships
Medical Technology, Health Information and Research Directorate, IMOH
Shai Melcer PhD
Head of the National Bio-convergence Program, Israel Innovation Authority (IIA)
Please select the Round Table you'd be interested in participating in:
Your details will be shared with the moderators of the round table that you attend.
Sorry. This form is no longer available.
